The IGNITION consortium aligned priorities to advance research on immune-mediated mechanisms leading to neurodegeneration

The Call is still open!

Applicants can find all information on the available positions, requirements, and application procedure — and submit their applications — via the IGNITION website:
https://ignition-consortium.eu/recruitment/

The IGNITION consortium held its online Kick-Off Meeting on 24 February 2026, bringing together 23 participants representing all project partners from across Europe. The meeting was opened by the project coordinator, Dr. Lidia Sabater (IDIBAPS), who welcomed the consortium members and highlighted the importance of collaborative efforts to advance research and training in immune-mediated mechanisms leading to neurodegeneration.

IGNITION focuses on understanding and addressing anti-IgLON5 disease, a rare and complex neurological condition first identified in 2014 by members of the current consortium. Through an integrated programme combining innovative research, clinical expertise, and cross-sectoral training, IGNITION will equip a new generation of researchers to tackle the mechanisms underlying this disorder and related forms of neurodegeneration.

The meeting included the participation of Roberta Gentile, the Project Officer from the Research Executive Agency (REA), who provided valuable guidance on project implementation and upcoming expectations within the framework of the Marie Skłodowska-Curie Actions.

Another relevant assitant to the IGNITION project’s Kick-Off meeting was Ava Easton from Encephalitis International, awarded an MBE by His Majesty The King in the New Year 2026 Honours List in recognition of her contributions to encephalitis research.

Led by Dr. Lidia Sabater, from the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), the IGNITION consortium brings together 10 partners from 8 European countries, as well as 13 associated partners spanning universities, research institutes, hospitals, SMEs, industry, a patient organisation, and a specialised training provider.

With strong engagement across all institutions and a clear roadmap ahead, IGNITION is now well positioned to advance its research and training goals and contribute to improving knowledge and future therapeutic strategies for autoimmune neurodegenerative diseases.